Triple Combination Therapy of Choroidal Neovascularization in AMD, a Cost Effect and Efficient Therapeutic Treatment
NCT ID: NCT02287298
Last Updated: 2016-04-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
400 participants
OBSERVATIONAL
2014-08-31
2015-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Combination Bevacizumab and Verteporfin (Two Different Sequences of Treatment)in Neovascular AMD
NCT00426998
Bevacizumab in Combination With Visudyne Photodynamic Therapy (PDT)
NCT00729846
Photodynamic Therapy Combined With Bevacizumab vs Bevacizumab Alone for Neovascular Age-related Macular Degeneration
NCT00696592
Intravitreal Bevacizumab Combined With PDT Versus Bevacizumab to Treat Exudative AMD
NCT00684853
Combination Therapy for Neovascular Age Related Macular Degeneration
NCT00447031
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
2006 TO 2010 PATIENTS
PATIENTS TREATED WITH TRIPLE COMBINATION THERAPY
TRIPLE COMBINATION THERAPY
TREATMENT WITH BEVACIZUMAB, DEXAMETHASONE AND PHOTODYNAMIC THERAPY
CURRENT PATIENTS
PATIENTS TREATED WITH TRIPLE COMBINATION THERAPY AND ADDITION OF 20 MG OF ORAL ZEAXANTHIN
TRIPLE COMBINATION THERAPY
TREATMENT WITH BEVACIZUMAB, DEXAMETHASONE AND PHOTODYNAMIC THERAPY
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
TRIPLE COMBINATION THERAPY
TREATMENT WITH BEVACIZUMAB, DEXAMETHASONE AND PHOTODYNAMIC THERAPY
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
50 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
The Retina Center of St. Louis County, PC
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
ROBERT J OLK, MD
Role: PRINCIPAL_INVESTIGATOR
THE RETINA CENTER
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
The Retina Center
St Louis, Missouri, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
14-07-0540
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.